Novartis "on track" with US H1N1 vaccine delivery
This article was originally published in Scrip
Executive Summary
Novartis says it is on track to produce 90 million units of bulk antigen, expected to result in 60 million doses of Influenza A (H1N1) vaccine, in line with its commitment to the US Department of Health and Human Services.